Updated analyses from 3 phase III trials continue to support Opdivo and its combinations for NSCLC

Study reinforces Tagrisso as the backbone therapy for EGFR-mutated lung cancer

New study results presented at the European Lung Cancer Congress 2025, March 26 to 29, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy and as the backbone for novel combinations, across stages and settings of epidermal growth factor receptor-mutated non-small cell lung cancer. Highlights include:

March 28, 2025

Vol.51 No.12

Drugs & Targets

EC expands approval for Breyanzi for r/r follicular lymphoma

The European Commission has granted approval to Breyanzi, a CD19-directed CAR T-cell therapy, for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

March 21, 2025

Vol.51 No.11

Drugs & Targets

EC approves Opdivo + Yervoy as first-line treatment for HCC

The European Commission approved Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma.

March 14, 2025

Vol.51 No.10

Drugs & Targets

FDA accepts sBLA for Opdivo + Yervoy in CRC

FDA accepted Bristol Myers Squibb’s supplemental biologics license application for Opdivo (nivolumab) plus Yervoy (ipilimumab) as a potential first-line treatment option for adult and pediatric patients (12 years and older) with unresectable or metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.

February 28, 2025

Vol.51 No.08

Capitol Hill White House

Amid funding cuts and firings, cancer groups seek relief from judges, in Congress—and in the court of public opinion

As NCI employees and others at HHS were receiving notices of termination, national cancer organizations called on Congress “to restore stability to NIH.”

February 21, 2025

Vol.51 No.07

By Claire Marie Porter, Jacquelyn Cobb and Paul Goldberg

Clinical Roundup

Opdivo + chemo improves OS in resectable lung cancer, phase III study shows

Bristol Myers Squibb announced the final analysis of overall survival from the phase III CheckMate-816 study, which evaluated Opdivo (nivolumab) in combination with platinum-doublet chemotherapy as a neoadjuvant treatment for adult patients with resectable (tumors ≥ 4 cm or node positive) non-small cell lung cancer.

February 21, 2025

Vol.51 No.07

Updated analyses from 3 phase III trials continue to support Opdivo and its combinations for NSCLC

YOU MAY BE INTERESTED IN

Study reinforces Tagrisso as the backbone therapy for EGFR-mutated lung cancer

EC expands approval for Breyanzi for r/r follicular lymphoma

EC approves Opdivo + Yervoy as first-line treatment for HCC

FDA accepts sBLA for Opdivo + Yervoy in CRC

Amid funding cuts and firings, cancer groups seek relief from judges, in Congress—and in the court of public opinion

Opdivo + chemo improves OS in resectable lung cancer, phase III study shows

Renew today!

Subscriber content

Never miss an issue!

Login